Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Roche Ends CellCept Trial After Increased Incidence of Rejection In Heart Transplant Patients

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Combination trial with Wyeth’s Rapamune does not establish safety and efficacy benefits.

You may also be interested in...



Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis

Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.

Aspreva, Roche Will Not Advance CellCept For Lupus Nephritis

Aspreva continues Phase III trial of CellCept to treat autoimmune disease pemphigus vulgaris.

Aspreva Will Not Pursue CellCept For Myasthenia Gravis After Phase III Failure

Study of Roche drug fails to meet both primary and secondary endpoints, company says.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS065675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By